Sebela Women’s Health Inc., a part of Sebela Pharmaceuticals, today announced Contraception published positive results online from the…
Year: 2025
Clarity receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer
Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop…
CHAMPS Group Purchasing Announces Channel Partnership With OMNIA Partners
Cleveland-based CHAMPS Group Purchasing, a national group purchasing organization (GPO) with more than 25,000 member locations…
Certification Training for Healthcare Providers: Reducing Pregnancy Complications and Chronic Childhood Diseases
Healthcare professionals are invited to attend an exclusive one-day certification training on Saturday, February 15, 2025, from 8:00…
Clinical trial published in Nature Medicine shows proof of concept of PAGE’s therapeutic approach
PAGE Therapeutics, a biotech company focused on tackling metastatic cancer spread at its root, is pleased…
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements
Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the “Company” or “Hoth Therapeutics”), a biopharmaceutical company, today announced that it…
Healthcare Services Market to Grow by USD 6.26 Trillion (2024-2028), Driven by Rising Chronic Disease Prevalence, Report Highlights AI-Powered Market Evolution
Report on how AI is driving market transformation – The global healthcare services market size is estimated to…
MedStar Health First in Maryland to Implant FDA Approved Tricuspid Valves in Patients Without Need for Open Heart Surgery
In two separate procedures, MedStar Health cardiac experts at MedStar Union Memorial Hospital reached new heights…
Springbok Analytics Announces $5M Series A to Advance Its Leadership in Muscle Health Analysis
Springbok Analytics (www.springbokanalytics.com), a leader in AI-driven muscle analytics, today announced the close of an oversubscribed $5M Series A…
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.
Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4…